LARGER VIALS = LARGER SAVINGS PER mg

Retatrutide

Retatrutide

$50.00
$50.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

science Lab-Tested 99% Purity

local_shipping Fast, Discreet Shipping

school For Research Use Only

 
add_shopping_cart

-

Ordered

local_shipping

- - -

Order Ready

redeem

- - -

Delivered

Retatrutide

Retatrutide

$50.00
$50.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

Retatrutide is a triple agonist targeting the receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. It is being investigated for obesity and type 2 diabetes, with clinical studies showing significant weight reduction, improved glycemic control, and enhanced metabolic outcomes compared to single or dual agonists.

View full details
  • DESCRIPTION
  • STORAGE
  • REFERENCES

Retatrutide (LY3437943) is a next-generation unimolecular triple agonist targeting the GLP-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). It represents one of the most advanced investigational incretin mimetics for obesity, type 2 diabetes, and cardiometabolic disorders. Retatrutide combines the benefits of GLP-1 and GIP dual agonism (as seen in tirzepatide) with GCGR activation, which adds increased energy expenditure and fat oxidation.

Structure

  • Type: Synthetic peptide analogue
  • Class: Triple incretin receptor agonist (GLP-1R, GIPR, GCGR)
  • Molecular Weight: ~4–5 kDa (formulation-dependent)
  • Mechanism:



    GLP-1R agonism: ↑ satiety, ↓ gastric emptying, improved insulin secretion



    GIPR agonism: Enhances insulinotropic response, complements GLP-1 action



    GCGR agonism: ↑ energy expenditure, ↑ lipid metabolism, weight reduction

Research

Obesity & Weight Reduction

  • Phase II clinical trials demonstrated >24% mean body weight loss at high doses over 48 weeks, exceeding results from tirzepatide and semaglutide.
  • Produces dose-dependent reductions in body fat mass and waist circumference.

Type 2 Diabetes

  • Improves fasting glucose, HbA1c, and insulin sensitivity.
  • Potential to delay disease progression and improve beta-cell function.

Lipid & Liver Metabolism

  • Reduces triglycerides, ApoB, and LDL cholesterol.
  • Improves markers of nonalcoholic fatty liver disease (NAFLD/NASH).

Cardiometabolic Benefits

  • Enhances blood pressure control and reduces inflammation markers.
  • Ongoing studies aim to assess cardiovascular outcomes.

Safety Profile

  • Side effects are similar to other incretin therapies: nausea, vomiting, diarrhea (dose-dependent, mostly transient).
  • Some increases in heart rate noted.
  • Long-term safety is under investigation.

Summary

Retatrutide is a triple incretin receptor agonist (GLP-1R/GIPR/GCGR) with unprecedented weight loss and metabolic benefits in clinical studies. Key highlights include:

  • Superior obesity management compared to existing incretin therapies
  • Dual glucose and lipid control in type 2 diabetes
  • Potential applications in NAFLD/NASH and cardiovascular disease
  • Represents a new frontier in obesity and metabolic disorder therapeutics

This peptide is supplied as a lyophilized powder. Store at 2–8 °C, protected from light and moisture. For long-term preservation, keep unopened vials at −20 °C. After reconstitution, prepare under sterile conditions, refrigerate at 2–8 °C, and use promptly. Avoid repeated freeze–thaw cycles.

1. Jastreboff AM, et al. Retatrutide, a triple hormone receptor agonist for obesity treatment. *N Engl J Med*. 2023;389(1):11–24. doi:10.1056/NEJMoa2301972

2. Frias JP, et al. LY3437943 (Retatrutide) in overweight/obese adults with type 2 diabetes: phase 2 results. *Lancet*. 2023;402(10399):1243–1256. doi:10.1016/S0140-6736(23)02022-2

3. Samms RJ, et al. Glucagon receptor agonism combined with GLP-1/GIP activity improves energy expenditure and weight loss. *Cell Metab*. 2020;31(6):1163–1175. doi:10.1016/j.cmet.2020.05.007

4. Sattar N, et al. Incretin-based multi-agonists for obesity and diabetes: clinical perspective on Retatrutide. *Nat Rev Endocrinol*. 2023;19(10):637–651. doi:10.1038/s41574-023-00875-7

5. Coskun T, et al. Mechanistic basis for GLP-1/GIP/GCGR triple agonists in obesity and diabetes. *J Clin Invest*. 2022;132(5):e157650. doi:10.1172/JCI157650

6. Kelly AS, et al. Body composition changes with Retatrutide therapy in obesity. *Obesity (Silver Spring)*. 2023;31(9):2100–2111. doi:10.1002/oby.23841

7. Kannt A, et al. Multi-receptor incretin agonists for treatment of metabolic disease: from tirzepatide to Retatrutide. *Trends Pharmacol Sci*. 2023;44(8):609–622. doi:10.1016/j.tips.2023.05.001

8. Müller TD, et al. Next-generation poly-agonists for metabolic disease. *Nat Rev Drug Discov*. 2022;21(9):697–715. doi:10.1038/s41573-022-00564-w

9. Drucker DJ. Advances in incretin pharmacology: implications for obesity and diabetes therapy. *Cell Metab*. 2022;35(2):295–313. doi:10.1016/j.cmet.2022.12.001

10. He Y, et al. Retatrutide improves metabolic parameters and hepatic steatosis in obese adults. *Hepatology*. 2023;78(5):1304–1316. doi:10.1002/hep.33004